< Back to latest news & events

Event

8th Annual Pharma IPR Conference 2019 – Mumbai

March 2019

Event date: 6th March 2019

HGF Partners Martyn Fish and Andy Camenisch will be attending the 8th Annual Pharma IPR Conference 6-8 March in Mumbai.

HGF Partner Andy Camenisch will be sharing insights on “Infringement of Second Medical Use in the EU”.

The Indian Pharma industry has generated astounding growth in the past decades fuelled by increasing burden of disease. In order for the Indian pharmaceutical industry to maximize its true potential, ideation, innovation and integration are pre-requisites to reaching this stupendous growth.

The numerous innovations leading to discovery of new life-saving drugs are through intellectual property rights (IPRs). IPR is a requirement for pharma companies for identification, planning, commercialisation and protection of invention.

The intellectual property market has manifested growth at an unprecedented pace. Risks abound and rights holders need strategic knowledge to maximize their success in the jurisdiction. The Patent Act, 1970 has played a significant role in taking India to the global patent arena.

Attendees

Martyn
Fish

Andrew
Camenisch

Latest updates

Avoiding Legal Pitfalls: The Notting Hill Bag Company's Costly Mistake

[2025] EWHC 1793 (IPEC) – Natasha Courtenay-Smith and Notting Hill Bag Company Limited v The Notting Hill Shopping Bag Company Limited, Nangialai Takanai, The Notting Hill Shopper Bag Ltd, Ehsanullah …

Read article
Event - 12th September 2025

Wolters Kluwer Breakfast Panel on AI & IP at AIPPI

Sofie McPherson, Patent Director at HGF, will be moderating a special breakfast panel session hosted by Wolters Kluwer at the AIPPI World Congress in Yokohama on 15 September 2025. Session …

Event details

T1465/23 – No Narrowing by Description—EPO Board Terminates Inventive Step Analysis for Arbitrary Modifications Citing G1/24 and G1/19

“The potential patentability of a specific narrow embodiment…cannot render a claim allowable which, due to its breadth, encompasses a multitude of other, non-inventive embodiments” – r. 3.5. Background EP3113515 was …

Read article

Wrestling with G1/24 – How should the claims be interpreted in view of the description?

In G1/24, the Enlarged Board of Appeal (EBA) codified how claims should be interpreted for assessing patentability: in consultation with the description. However, the decision was light on how, in …

Read article

Welcome to HGF Presents - New Video Series

Introducing HGF Presents a new video series delivering practical insights into European Patent Law and practice. Curated by our leading experts in chemistry, life sciences, technology & engineering, each concise …

Read article

Seminar on Incorporating Trade Secrets into your IP Strategy

HGF is hosting a Seminar on Incorporating Trade Secrets into your IP Strategy which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 10th …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

Providing Enabling Disclosure for AI inventions at the EPO

  Video overview: The equivalent to the enablement requirement in the US at the EPO is Sufficiency. There is an increasing trend for the sufficiency of AI related patent applications …

Read article
See all updates